Page 1

EX - 99.12 staa - ex991_6.htm EX - 99.1 STAARSURGICAL " TM Exhibit 99.1 STAAR Surgical Reports Record First Quarter 2021 Net Sales of $ 50.8 Million Up 44 % Y / Y First Quarter ICL Sales Up 58 % Y / Y and Units Up 54 % Y / Y Announces Submission of Clinical Trial Data to U.S. FDA for EVO Family of Myopia Lenses Introduces Net Sales Outlook of Approximately $ 215 Million to $ 217 Million for Full Year 2021 ___ LAKE FOREST , CA , May 5 , 2021 STAAR Surgical Company ( NASDAQ : STAA ) , a leading developer , manufacturer and marketer of implantable lenses and companion delivery systems for the eye , today reported financial results for the first quarter ended April 2 , 2021 . First Quarter 2021 Overview • Record Quarterly Net Sales of $ 50.8 Million Up 44 % from the Prior Year Quarter Record Quarterly ICL Sales of $ 46.5 Million Up 58 % from the Prior Year Quarter Record Quarterly ICL Units , Up 54 % from the Prior Year Quarter • Gross Margin at 77.1 % vs. 70.4 % in the Prior Year Quarter Net Income of $ 0.10 per Share vs. Prior Year Quarter Net Loss of Approximately Breakeven Cash and Cash Equivalents Ended the Quarter at $ 162.3 Million Up from $ 152.5 Million in Q4 2020 “ Every major market delivered outstanding performance during the first quarter of 2021 providing a record breaking quarterly achievement of net sales of $ 50.8 million . First quarter ICL sales of $ 46.5 Million and unit growth of 54 % continued the increasing momentum from second half 2020 results and represents a return to the strong demand for ICL lenses we experienced in January 2020 prior to the pandemic taking hold , ” said Caren Mason , President and CEO of STAAR Surgical . “ ICL unit growth in the first quarter , year over year , included China up 63 % , Japan up 72 % , Korea up 29 % , Rest of Asia Pacific up 63 % , Spain up 42 % , Germany up 48 % , Distributor Markets in Europe up 54 % , and the U.S. up 46 % . " " The record results for the first quarter of 2021 demonstrate that the promise for a lens - based future of refractive vision correction is accelerating , led by STAAR's EVO Visian family of implantable Collamer lenses . STAAR's imperatives around surgeon training and partnership , clinical support and extraordinary consumer outreach such as our newest campaign in Japan , continue to be the underpinnings of our excellent results . In China , the largest market for refractive surgery in the world , we now turn our attention to preparing for and delivering excellence during the upcoming busy implant season which typically begins in June . In late April , the FDA received our clinical data for our EVO family of myopia lenses with the goal of bringing EVO to the U.S. market later this year . We also recently launched the third phase of our newest commercial initiative in the U.S. , Refractive ReLook , a program focused on driving adoption of lower diopter lenses in the U.S. We have increasing visibility into market dynamics and expect the momentum in our ICL business to continue . Therefore , today , we are introducing a sales outlook for fiscal 2021 full year net sales of approximately $ 215 million to $ 217 million which represents an exciting level of growth , exceeding 30 % year over year even taking into account the strong performance in the second half of 2020 , " concluded Ms. Mason . Financial Overview – Q1 2021 Net sales were $ 50.8 million for the first quarter of 2021 , up 44 % compared to $ 35.2 million reported in the prior year quarter . The sales increase was driven by ICL net sales and unit growth up 58 % and 54 % , respectively , as compared to the prior year period . Other Product Sales decreased 27 % compared to the prior year quarter due primarily to lower